Literature DB >> 32340063

Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports.

Einars Kupats1,2, Jelena Vrublevska3, Baiba Zvejniece1, Edijs Vavers1, Gundega Stelfa1,4, Liga Zvejniece1, Maija Dambrova1,5.   

Abstract

Phenibut is a nootropic drug that exerts anxiolytic and antinociceptive effects by acting on the GABAB receptor and the α2-δ subunit of voltage-dependent calcium channels. An increased number of reports of dependence to and intoxication by phenibut purchased online on the one hand and the wide prescription of phenibut in Eastern Europe for more than half a century on the other hand have resulted in a number of controversies regarding its use. In this review, we have summarized currently available information from case reports of phenibut dependence and intoxication and safety data from clinical trials. We included 14 dependence and intoxication case reports (16 patients) and reviewed 11 phenibut clinical trials (583 patients). The clinical symptoms in the case reports included cardiovascular effects, insomnia, anxiety and agitation, hallucinations, and depressed level of consciousness. In addition, the doses used (0.5-100 g/day) were much higher than the recommended daily dose (0.25-2 g/day). An analysis of phenibut side effects described in the clinical trials showed adverse events in only 5.66% of patients, and the most reported side effect was somnolence (1.89%). There are discrepancies in the reported side effects of phenibut in clinical trials compared to those reported in cases of online-purchased phenibut dependence and intoxication. The current systematic review provides evidence that, at therapeutic doses, phenibut is safe and well tolerated with minor adverse effects, but questions regarding the quality of phenibut obtained online and the contribution of alcohol and other drug abuse to phenibut dependence and intoxication remain open. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32340063     DOI: 10.1055/a-1151-5017

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  3 in total

1.  Mitochondrial-Protective Effects of R-Phenibut after Experimental Traumatic Brain Injury.

Authors:  Einars Kupats; Gundega Stelfa; Baiba Zvejniece; Solveiga Grinberga; Edijs Vavers; Marina Makrecka-Kuka; Baiba Svalbe; Liga Zvejniece; Maija Dambrova
Journal:  Oxid Med Cell Longev       Date:  2020-11-21       Impact factor: 6.543

2.  Qualitative fingerprinting of psychoactive pharmaceuticals, illicit drugs, and related human metabolites in wastewater: A year-long study from Riga, Latvia.

Authors:  Ingus Perkons; Laura Elina Tomsone; Veronika Sukajeva; Romans Neilands; Kristina Kokina; Iveta Pugajeva
Journal:  J Environ Chem Eng       Date:  2022-06-18

Review 3.  Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs.

Authors:  Matěj Malík; Pavel Tlustoš
Journal:  Nutrients       Date:  2022-08-17       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.